A case for developing antiviral drugs against polio.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antiviral Research

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.antiviral.2008.04.002PMID 18513807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.

  2008cited by this paper
• Potential Use of Antiviral Agents in Polio Eradication

  2008cited by this paper
• John F. Enders lecture 2006: antivirals for influenza.

  2007cited by this paper
• Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.

  2007cited by this paper
• Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico.

  2007cited by this paper
• In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease

  2007cited by this paper
• Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

  2007cited by this paper
• Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba

  2007cited by this paper
• NIAID resources for developing new therapies for severe viral infections

  2007cited by this paper
• Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.

  2007cited by this paper
• Vaccine-derived poliovirus from long term excretors and the end game of polio eradication.

  2006cited by this paper
• Rhinovirus chemotherapy

  2006cited by this paper
• Vaccine-derived polioviruses and the endgame strategy for global polio eradication.

  2005cited by this paper
• 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder.

  2005cited by this paper
• Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril.

  2005cited by this paper
• Conservation of Amino Acids in Human Rhinovirus 3C Protease Correlates with Broad-Spectrum Antiviral Activity of Rupintrivir, a Novel Human Rhinovirus 3C Protease Inhibitor

  2005cited by this paper
• In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

  2005cited by this paper
• A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future.

  2005cited by this paper
• Influenza Virus Susceptibility and Resistance to Oseltamivir

  2005cited by this paper
• Immune responses and the emergence of drug–resistant virus strains in vivo

  2004cited by this paper
• In Vitro Activity of Expanded-Spectrum Pyridazinyl Oxime Ethers Related to Pirodavir: Novel Capsid-Binding Inhibitors with Potent Antipicornavirus Activity

  2004cited by this paper
• The Poliovirus Replication Machinery Can Escape Inhibition by an Antiviral Drug That Targets a Host Cell Protein

  2004cited by this paper
• Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

  2004cited by this paper
• An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.

  2003cited by this paper
• [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril].

  2003cited by this paper
• Polio-ähnliche Myelitis durch Coxsackie-Virus B 3: Verlauf unter Pleconaril-Behandlung

  2003cited by this paper
• Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis.

  2003cited by this paper
• Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials

  2003cited by this paper
• Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis.

  2003cited by this paper
• Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers

  2003cited by this paper
• Severe Coxsackie virus B infection in preterm newborns treated with pleconaril

  2002cited by this paper
• Oral Pleconaril Treatment of Picornavirus-Associated Viral Respiratory Illness in Adults: Efficacy and Tolerability in Phase II Clinical Trials

  2002cited by this paper
• Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus

  2002cited by this paper
• Picornavirus inhibitors

  2002cited by this paper
• A Single Amino Acid Substitution in the ICP27 Protein of Herpes Simplex Virus Type 1 Is Responsible for Its Resistance to Leptomycin B

  2001cited by this paper
• Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion

  2000cited by this paper
• Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection.

  2000cited by this paper
• Mutations in the 2C Region of Poliovirus Responsible for Altered Sensitivity to Benzimidazole Derivatives

  2000cited by this paper
• Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants.

  1999cited by this paper
• In Vitro Antiviral Activity of AG7088, a Potent Inhibitor of Human Rhinovirus 3C Protease

  1999cited by this paper
• Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient

  1998cited by this paper
• Treatment of human enterovirus infections.

  1998cited by this paper
• SCH 48973: a potent, broad-spectrum, antienterovirus compound

  1997cited by this paper
• Antipicornavirus activity of SCH 47802 and analogs: in vitro and in vivo studies.

  1996cited by this paper
• Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins

  1996cited by this paper
• Intranasal pirodavir (R77,975) treatment of rhinovirus colds

  1995cited by this paper
• The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus

  1995cited by this paper
• Discovery and development of antipicornaviral agents.

  1993cited by this paper
• Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A.

  1992cited by this paper
• Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.

  1992cited by this paper
• Inhibition of poliovirus RNA synthesis by brefeldin A

  1992cited by this paper
• Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

  1992cited by this paper
• Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410

  1990cited by this paper
• Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound

  1989cited by this paper
• The attenuation of poliovirus neurovirulence.

  1987cited by this paper
• Studies of rhinovirus resistant to an antiviral chalcone.

  1987cited by this paper
• Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug

  1986cited by this paper
• Oral efficacy of WIN 51711 in mice infected with human poliovirus

  1986cited by this paper
• Antiviral agents against picornaviruses.

  1985cited by this paper
• Action of human lymphoblastoid interferon on HeLa cells infected with RNA-containing animal viruses.

  1984cited by this paper
• Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1-[(1-methylethyl)sulfonyl]-1H-benzimidazol-2-amine. Inhibitors of rhinovirus multiplication.

  1980cited by this paper
• Inhibition of enterovirus cytopathic effects by 2-(alpha-hydroxybenzyl)-benzimidazole.

  1966cited by this paper
• Inhibition of Enterovirus Cytopathic Effects by 2-(α-Hydroxybenzyl)-Benzimidazole

  1966cited by this paper
• Poliovirus-induced RNA polymerase and the effects of virus-specific inhibitors on its production.

  1963cited by this paper
• Antiviral Effect of Guanidine

  1961cited by this paper
• The effect of guanidine: (1). On experimental poliomyelitis induced by oral administration of virus to cynomolgus monkeys; (2). On naturally occurring enteroviruses of cynomolgus monkeys.

  1961cited by this paper
• The effect of guanidine: (1). On experimental poliomyelitis induced by oral administration of virus to cynomolgus monkeys; (2). On naturally occurring enteroviruses of cynomolgus monkeys.

  1961cited by this paper
• Influence of pyrimidine analogs and related compounds on the propagation of poliomyelitis virus in tissue culture.

  1957cited by this paper
• INFLUENCE OF PYRIMIDINE ANALOGS AND RELATED COMPOUNDS ON THE PROPAGATION OF POLIOMYELITIS VIRUS IN TISSUE CULTURE

  1957cited by this paper
• Antiviral Action of a Mold Filtrate on Experimental Poliomyelitis in Gynomolgus Monkeys.∗

  1954cited by this paper
• Effect of Fluoroacetate Upon Poliomyelitis in Monkeys.∗

  1954cited by this paper
• Effect of Benzimidazole on Experimental Poliomyelitis in Mice and Monkeys.∗

  1953cited by this paper
• The influence of chemicals on the propagation of poliomyelitis virus in tissue culture.

  1952cited by this paper

• Pyrazole-based N-phenyl pyrazolines: Synthesis, docking, and pharmacological evaluation

  2024cites this paper
• Tata Laksana Komprehensif Terkini Penanganan Re-Emergensi Hand, Foot, and Mouth Disease (HFMD) di Indonesia: Tinjauan Lingkup

  2024cites this paper
• An automated assay platform for the evaluation of antiviral compounds against polioviruses,

  2024cites this paper
• Characterization of Anti-Poliovirus Compounds Isolated from Edible Plants

  2023cites this paper
• Rubella virus chronic inflammatory disease and other unusual viral phenotypes in inborn errors of immunity

  2023cites this paper
• Biographical Feature: Marc S. Collett (23 May 1951–11 June 2022): the Battle against Viral Disease Has Lost a Valiant Warrior, and the World Has Lost a Splendid Human Being

  2022cites this paper
• A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation

  2022cites this paper
• Controlled Human Infection Models To Accelerate Vaccine Development

  2022cites this paper
• Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs

  2021cites this paper
• Nonpolio Enteroviruses, Polioviruses, and Human CNS Infections

  2020cites this paper
• Poliovirus Polymerase

  2019cites this paper
• In vitro Activity of the Novel Pyrimidines and Their Condensed Derivatives Against Poliovirus

  2019cites this paper
• Polio Vaccines: Present and Future

  2018cites this paper
• The Endgame for Elimination of Polioviruses

  2018cites this paper
• Crystal structure of a soluble fragment of poliovirus 2CATPase

  2018cites this paper
• Machine Learning Toward Infectious Disease Treatment

  2018cites this paper
• Poliovirus Studies during the Endgame of the Polio Eradication Program.

  2017cites this paper
• Cell-Based High-Throughput Screening Assay Identifies 2',2'-Difluoro-2'-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent.

  2017cites this paper
• MicroRNA-555 has potent antiviral properties against poliovirus.

  2016cites this paper
• Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model

  2016cites this paper
• Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy.

  2016cites this paper
• A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

  2015cites this paper
• Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses

  2015cites this paper
• In Vitro Efficacy of Antiviral Compounds against Enterovirus D68

  2015cites this paper
• Antivirals against Enteroviruses: A Critical Review from a Public-Health Perspective

  2015influential citation
• Effect of 1-(phenyl)-N’-(4-methoxybenzylidene)-9H-pyrido[3,4-b] indole-3-carbohydrazide on in vitro poliovirus replication

  2015cites this paper
• National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication

  2014cites this paper
• Dominant drug targets suppress the emergence of antiviral resistance

  2014cites this paper
• H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.

  2014cites this paper
• Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

  2014influential citation
• New Small-Molecule Inhibitors Effectively Blocking Picornavirus Replication

  2014cites this paper
• The enteroviruses: problems in need of treatments.

  2014cites this paper
• Global polio perspective

  2014cites this paper
• Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.

  2014cites this paper
• Novel Technologies for Vaccine Development

  2014cites this paper
• Synthesis, studies and in vitro antibacterial activity of some 5-(thiophene-2-yl)-phenyl pyrazoline derivatives

  2014cites this paper
• Current Status and Future of Polio Vaccines and Vaccination

  2014cites this paper
• An integrated bioinformatics and computational biophysics approach to enterovirus surveillance and research

  2014cites this paper
• Compoundsof Minor Enviroxime-Like Oxysterol-Binding Protein Family I Is the

  2014cites this paper
• The final stages of the global eradication of poliomyelitis

  2013cites this paper
• PicornavirusesAntiviral Effects against Acceptor Inhibitors and Their Structure-Based Design of Michael 3C Protease of Enterovirus 68:

  2013cites this paper
• Enteroviruses : Problems in need of treatments 3 Enterovirus 71 : the new poliovirus

  2013influential citation
• Oxysterol-Binding Protein Family I Is the Target of Minor Enviroxime-Like Compounds

  2013cites this paper
• Intervention strategies for emerging viruses: use of antivirals

  2013cites this paper
• Challenges to the eradication of wild-type poliovirus ( a ) Poor immunogenicity of OPV in certain populations

  2013cites this paper
• 3 C Protease of Enterovirus 68 : Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against

  2013cites this paper
• 3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses

  2013cites this paper
• Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.

  2013cites this paper
• [Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection].

  2013cites this paper
• Antipoliovirus Activity Target of Enviroxime-Like Compounds for Phosphatidylinositol 4-Kinase III Beta Is a

  2013cites this paper
• Valosin-Containing Protein (VCP/p97) Is Required for Poliovirus Replication and Is Involved in Cellular Protein Secretion Pathway in Poliovirus Infection

  2012cites this paper
• Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073

  2012cites this paper
• Antiviral activity of fractions from leaves of Piper regnelli var. pallescens

  2012cites this paper
• Characterization of viral proteases from Norwalk virus, poliovirus, and transmissible gastroenteritis virus using a fluorescence resonance energy transfer assay

  2012cites this paper
• Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis

  2012cites this paper
• Picornavirus non-structural proteins as targets for new anti-virals with broad activity.

  2011cites this paper
• Antiviral Activity of 3(2H)- and 6-Chloro-3(2H)-Isoflavenes against Highly Diverged, Neurovirulent Vaccine-Derived, Type2 Poliovirus Sewage Isolates

  2011cites this paper
• Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains

  2011cites this paper
• Towards the design of combination therapy for the treatment of enterovirus infections.

  2011cites this paper
• Immunogenicity of Inactivated Polio Vaccine with Concurrent Antiviral V-073 Administration in Mice

  2011cites this paper
• Poliovirus 3C proteinase inhibition by organotelluranes

  2011cites this paper
• A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.

  2010cites this paper
• Phosphatidylinositol 4-Kinase III Beta Is a Target of Enviroxime-Like Compounds for Antipoliovirus Activity

  2010cites this paper
• In vitro antiviral activity of single domain antibody fragments against poliovirus.

  2010cites this paper
• Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.

  2010cites this paper
• Long-range interaction networks in the function and fidelity of poliovirus RNA-dependent RNA polymerase studied by nuclear magnetic resonance.

  2010cites this paper
• The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox.

  2010cites this paper
• Structure-based antivirals for emerging and neglected RNA viruses: an emerging field for medicinal chemistry in academia.

  2010cites this paper
• David Neubauer, Jutta Steinberger, and Tim Skern

  2009cites this paper
• Protein requirements for the initiation of poliovirus negative-strand RNA synthesis

  2009cites this paper
• In Vitro Antiviral Activity of V-073 against Polioviruses

  2009cites this paper
• Picornaviruses

  2009cites this paper